Jon Congleton Sells 15,271 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 15,271 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the sale, the chief executive officer now directly owns 895,941 shares of the company’s stock, valued at $12,113,122.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Mineralys Therapeutics Stock Performance

MLYS opened at $13.88 on Friday. Mineralys Therapeutics, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $16.91. The firm has a 50-day moving average of $12.05 and a 200 day moving average of $12.44. The firm has a market cap of $689.13 million, a P/E ratio of -6.34 and a beta of 1.93.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same period in the previous year, the firm posted ($0.31) EPS. Equities research analysts predict that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MLYS. SG Americas Securities LLC purchased a new stake in shares of Mineralys Therapeutics in the third quarter worth about $110,000. Nantahala Capital Management LLC lifted its stake in Mineralys Therapeutics by 60.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock worth $6,230,000 after purchasing an additional 200,000 shares in the last quarter. Driehaus Capital Management LLC boosted its holdings in Mineralys Therapeutics by 40.4% in the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock valued at $3,011,000 after purchasing an additional 74,074 shares during the period. Lion Point Capital LP grew its position in shares of Mineralys Therapeutics by 31.7% during the 2nd quarter. Lion Point Capital LP now owns 79,000 shares of the company’s stock valued at $924,000 after purchasing an additional 19,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Mineralys Therapeutics in the second quarter worth $145,000. Institutional investors own 84.46% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a report on Thursday, August 15th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.